Xilio Therapeutics, Inc. / Fundamentals
Income statement
- Net revenue
€12.87M - Cost of goods sold
€0.00 - Gross profit
€12.87M - SG&A expenses
€24.42M - R&D expenses
€37.06M - EBITDA
-€47.20M - D&A
€1.40M - EBIT
-€48.57M - Interest expenses
€0.00 - EBT
-€48.24M - Tax expenses
€0.00 - Net income
-€48.24M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
€31.81M - Changes in working capital
-€1.54M - Operating cash flow
-€11.44M - Capex
€375.80K - Other investing cash flow
€0.00 - Net investing cash flow
-€375.80K - Total cash dividends paid
€0.00 - Issuance of common stock
€32.33M - Debt repayment
-€6.01K - Other financing cash flow
€7.08M - Net financing cash flow
€51.82M - Foreign exchange effects
€0.00 - Net change in cash
€40.01M - Cash at end of period
€105.83M - Free cash flow
-€11.06M
Balance sheet
- Cash and cash equivalents
€104.29M - Cash and short-term investments
€104.29M - Total receivables
€0.00 - Inventory
€0.00 - Other current assets
€1.86M - Total current assets
€106.15M - Property, plant & equipment
€7.12M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€1.54M - Other non-current assets
€0.00 - Total non-current assets
€8.66M - Total assets
€114.81M - Accounts payable
€3.52M - Short-term debt
€1.08M - Other current liabilities
€4.82M - Total current liabilities
€45.70M - Long-term debt
€5.41M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€33.08M - Total non-current liabilities
€63.05M - Total liabilities
€108.75M - Common stock
€4.29K - Retained earnings
-€354.24M - Other equity
€0.00 - Total equity
€6.07M - Total liabilities and shareholders' equity
€114.81M
Company information
- Market capitalization
€29.83M - Employees
64 - Enterprise Value
-€45.32M
Company ratios
- Gross margin
-
100.0% Much better than peer group: -52.6% - EBITDA margin
-
-366.7% Much better than peer group: -3,629.9% - EBIT margin
-
-377.4% Much better than peer group: -9,137.3% - EBT margin
-
-374.8% Much better than peer group: -276,024.2% - Net margin
-
-374.8% Much better than peer group: -3,401.6% - ROE
-
-795.3% Much worse than peer group: -119.7% - ROA
-
-42.0% Much better than peer group: -241.7% - Asset turnover
-
11.2% Much worse than peer group: 112.0% - FCF margin
-
-91.8% Much better than peer group: -19,188.0% - FCF yield
-39.6% - Efficiency ratio
466.7% - Net sales per employee
-
€201.11K - Net income per employee
-
-€753.73K